SCHEMBL2991055

SCHEMBL2991055

COCCNC(=O)C1CC2CNCC2C1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 7/20 0.56
CHRNA4 P43681 7/20 0.56
CHRNB4 P30926 5/20 0.56
CHRNA3 P32297 5/20 0.56
CHRNA7 P36544 4/20 0.56
MAPT P10636 1/20 0.48
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
HPGD P15428 2/20 0.44
CYP3A4 P08684 1/20 0.43
ALDH1A1 P00352 2/20 0.42
CYP2C19 P33261 1/20 0.42
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30283073 0.86 MAPT (0.49) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL2988026 0.85 CHRNB2 (0.69) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL16799726 0.78 MAPT (0.59) MAPTMEN1KMT2AHPGDCYP3A4
SCHEMBL1438746 0.78 GNAI3 (0.58) MAPTMEN1KMT2AHPGDCYP3A4
SCHEMBL2991035 0.77 CHRNB2 (0.66) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL40045 0.76 REN (0.49) MAPTMEN1KMT2AHPGDCYP3A4
SCHEMBL40044 0.76 REN (0.49) MAPTMEN1KMT2AHPGDCYP3A4
Hydrochloric Acid SCHEMBL21641162 0.75 MAPT (0.41) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL31524234 0.75 KMT2A (0.56) MAPTMEN1KMT2AHPGDCYP3A4
Hydrochloric Acid SCHEMBL21640532 0.75 CYP3A4 (0.55) HPGDCYP3A4ALDH1A1CYP2C19L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198296-B2 Sub-type selective azabicycloalkane derivatives TARGACEPT, INC. (US) 2012-06-12 US disclosed
US-20100173968-A1 SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES TARGACEPT, INC. (US) 2010-07-08 US disclosed
EP-2139857-A1 SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES Targacept Inc. (US) 2010-01-06 EP disclosed
WO-2008121686-A1 SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES TARGACEPT, INC. (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173968-A1 SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES CHRNB2, CHRNB4, CHRNA4 CHRNB2 1/4885CHRNA4 3/4885CHRNB4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.